Tag

Erasca, Inc.

1 article

Erasca Shares Fall 5% on Trial Data

Erasca shares fell about 5% in after‑hours trading after releasing Phase 1 data for its pan‑RAS drug ERAS‑0015. In KRAS G12X non‑small cell lung cancer, ERAS‑0015 achieved a 62% unconfirmed overall re